PROCEPT BioRobotics

🚀 We’re excited to announce the launch of the new PROCEPT Global website! 🌐 🔑 Key Features: A dedicated Healthcare Provider section for our global audience, featuring the latest content on our HYDROS Robotic System and AquaBeam Robotic System. Investor resources with streamlined access to company performance and updates. A Careers section showcasing opportunities for those looking to join our mission. Check it out, explore, and let us know what you think! 👇 https://bit.ly/4dzPKXW #Procept #Aquablation #Innovation #ProstateCare #Healthcare #Investors #Careers #WebsiteLaunch

🚀 PROCEPT BioRobotics announces Q3 2024 results, increases 2024 revenue and adjusted EBITDA guidance 📈 Q3 2024 Highlights: • Total revenue of $58.4 million, up 66% YoY • Sold 45 robotic systems in the U.S. • U.S. handpiece and consumables revenue of $29.6M, a 74% increase YoY • Achieved record gross margins of 63.2% in the third quarter • Received FDA clearance and launched the HYDROS™ Robotic System in August Thank you for your continued support as we advance patient care through transformative solutions in urology! https://bit.ly/3AhWdcI #PROCEPTBioRobotics #AquablationTherapy #FinancialResults #HealthcareInnovation

PROCEPT BioRobotics is excited to announce FDA approval of the WATER IV Prostate Cancer Study, a pivotal IDE clinical trial comparing Aquablation therapy to radical prostatectomy. The WATER IV PCa study is a global multicenter, prospective, randomized controlled trial assessing the safety and efficacy of Aquablation therapy vs. prostatectomy in men with localized prostate cancer for 280 patients with 10-year follow up. We look forward to sharing continued updates as the study reaches key milestones. “WATER IV PCa, a unique trial design focusing on harm reduction by using Aquablation as first line treatment in comparison to radical prostatectomy, has the potential to be a game-changer in the way urologists treat localized prostate cancer for millions of men.” Dr. Inderbir Gill, Chairman, Catherine & Joseph Aresty Department of Urology and founding executive director of USC Urology, part of Keck Medicine of USC. https://bit.ly/4dy7mDz *Investigational Use Only

Join us at the Western Section AUA Meeting in Koloa, HI, from October 29 – November 1, 2024! Come visit us at booth #116 to discover the HYDROS™ Robotic System, the next-generation, AI-powered robotic platform for Aquablation® therapy. The HYDROS system features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. A perfect opportunity to learn more about the HYDROS system designed to improve efficiency, enhance surgeon and staff experience, and deliver an accurate and consistent treatment plan for better clinical outcomes. Learn more about the HYDROS System on our new PROCEPT BioRobotics website: https://bit.ly/3AsgxYA #HYDROS #AquablationTherapy #PROCEPTBioRobotics Safety information https://bit.ly/3TChpkT

Join us at the Western Section AUA Meeting in Koloa, HI, from October 29 – November 1, 2024! Come visit us at booth #116 to discover the HYDROS™ Robotic System, the next-generation, AI-powered robotic platform for Aquablation® therapy. The HYDROS system features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. A perfect opportunity to learn more about the HYDROS system designed to improve efficiency, enhance surgeon and staff experience, and deliver an accurate and consistent treatment plan for better clinical outcomes. Learn more about the HYDROS System on our new PROCEPT BioRobotics website: https://bit.ly/3AsgxYA #HYDROS #AquablationTherapy #PROCEPTBioRobotics Safety information https://bit.ly/3TChpkT

Dr. Ani highlights how Aquablation® therapy is transforming BPH treatment, providing patients with better urinary flow while minimizing side effects. Learn more on our new PROCEPT BioRobotics website and start changing lives today.https://bit.ly/3AsgxYA #DoctorTestimonial #AquablationTherapy Not all patients will experience the same results. For safety information https://bit.ly/3TChpkT

Attendees at the Mid-Atlantic Section AUA Annual Meeting had the opportunity to get hands-on with the latest advancements in technology from PROCEPT BioRobotics. We were excited to showcase the HYDROS™ Robotic System—an advanced, AI-powered platform to deliver Aquablation® therapy. Learn more about the HYDROS system on our new PROCEPT BioRobotics website: https://bit.ly/3AsgxYA #MAAUA24

We’re excited to see everyone at the South-Central Section Meeting in Colorado Springs, CO, from October 30 – November 1, 2024! Visit our booth to discover the HYDROS™ Robotic System, the next-generation, AI-powered robotic platform for Aquablation® therapy. This cutting-edge BPH treatment offers clinically proven, lasting symptom relief while preserving sexual function and continence in prostates of all shapes and sizes.1,2 Join us to experience the HYDROS system and how it is designed to deliver an accurate and consistent treatment plan for better clinical outcomes. Reserve your spot now: https://bit.ly/3ZUnKv2 Learn more about the HYDROS system on our new PROCEPT BioRobotics website: https://bit.ly/3AsgxYA #HYDROS #AquablationTherapy #PROCEPTBioRobotics 1. Gilling PJ, et al. Can J Urol. 2022. 2. Bhojani N, et al. J Urol. 2023. Safety information https://bit.ly/3TChpkT

Check out Dr. Lewis Kriteman's tips for urologists adopting the HYDROS™ Robotic System in this Urology Times interview. https://bit.ly/3TJNA0Z Learn more on our new PROCEPT BioRobotics website: https://bit.ly/3AsgxYA

Exploring same-day discharge (SDD) after Aquablation® therapy? A recent study shows it's not only feasible but highly effective and safe for patients with BPH. 98% of patients were successfully discharged on the same day, with improved urinary flow rates and minimal complications. As we continue to prioritize patient outcomes and resource efficiency, SDD with Aquablation® therapy could represent a new standard in outpatient BPH care. Learn more: https://bit.ly/4dr7wwA Not all patients will experience the same results. For safety information https://bit.ly/3TChpkT